Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
31 Mar 2020
When treating fibromyalgia patients with low-dose naltrexone, the 4.5-mg dose appears to be a good choice, according to a recent study.
Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.

Ilaprazole not inferior to rabeprazole in treatment of duodenal ulcer

06 Oct 2019

The efficacy of ilaprazole 5 mg appears to be on a par with rabeprazole 10 mg in treating duodenal ulcer, a study has shown. In addition, there is a dose-effect relationship between 5- and 10-mg ilaprazole.

In this double-blind, parallel, randomized study, patients aged >18 years with at least one endoscopically confirmed active nonmalignant duodenal ulcer received either rabeprazole 10 mg or ilaprazole 5/10 mg for 4 weeks. Ulcer healing was characterized by resolution from active to scarring stage.

The investigators assessed symptoms relief using a graded score and evaluated the safety and tolerability of these study drugs based on clinical assessments.

In total, 390 patients completed the study. Duodenal ulcer was successfully healed in 75.38 percent of patients in the rabeprazole 10-mg group, 77.86 percent in the ilaprazole 5-mg group and 83.72 percent in the ilaprazole 10-mg group after 4 weeks of treatment.

The 4-week healing rate difference between rabeprazole 10 mg and ilaprazole 5 mg was 2.58 percent (95 percent CI, –7.79 percent to 12.74 percent), showing the noninferiority of the latter. In logistic regression analysis, ilaprazole 10 mg was superior to ilaprazole 5 mg at week 2 (odds ratio, 1.92, 1.02–3.59; p=0.04).

Eighty percent of patients became asymptomatic after treatment. All three drug groups showed comparable efficacy and safety profile at the dosages administered.

“Ilaprazole is a kind of benzimidazole proton-pump inhibitor, which was confirmed efficacious and safe in treatment of duodenal ulcer,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
31 Mar 2020
When treating fibromyalgia patients with low-dose naltrexone, the 4.5-mg dose appears to be a good choice, according to a recent study.
Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.